Abstract: The present invention relates to a von Willebrand factor composition for the prevention and/or the treatment of haemorrhage and/or bleeding in patients with mechanical circulatory support.

Abstract: The present invention relates to a von Willebrand factor composition for the prevention and/or the treatment of haemorrhage and/or bleeding in patients with mechanical circulatory support.

Abstract: The present invention relates to a von Willebrand factor composition for the prevention and/or the treatment of haemorrhage and/or bleeding in patients with mechanical circulatory support.

Abstract: The invention relates to a system for electroencephalographic detection of an improper adjustment of a ventilator used on a mammal. The system includes an electroencephalograph, capable of measuring, as a function of time, an electroencephalographic signal representative of a breathing process; and an input for receiving a respiratory initiation signal, different from the electroencephalographic signal, capable of indicating a respiratory initiation time. The detection system further includes means for specifying a beta frequency band comprised between 15 and 30 Hz and with a width comprising between 5 and 10 Hz; means for processing the measured electroencephalographic signal, configured for processing the measured electroencephalographic signal as it is being acquired, in the sole specified beta frequency band; and means for identifying, for each breathing cycle, an improper adjustment of the ventilator from the electroencephalographic signals processed in the sole beta frequency band.

Abstract: A method for producing a polypeptide, includes at least one native ligation step using a peptide functionalized with a selenium group. The selenium peptides and compounds are also described.

Abstract: The present invention concerns an in vitro method for diagnosing invasive candidiasis (IC) in a subject which comprises detecting the presence of a Candida glycan and detecting the presence of antibody directed against a protein selected from the group consisting of fructose bisphosphate aldolase (Fba1), enolase 1 (Eno1), heat shock protein 90 (Hsp90), hyphal wall protein (Hwp1), and mannoprotein 65 (Mp65) in a blood, plasma or serum sample of the subject. The invention also relates to a method of determining a suitable treatment regimen for a patient and to a kit for implanting the methods described herein.

Abstract: A method for producing a polypeptide, includes at least one native ligation step using a peptide functionalized with a selenium group. The selenium peptides and compounds are also described.

Abstract: The present invention relates to compounds having the following Formula (I) for use in the prevention and/or the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs.

Abstract: The invention relates to a system for electroencephalographic detection of an improper adjustment of a ventilator used on a mammal. The system includes an electroencephalograph, capable of measuring, as a function of time, an electroencephalographic signal representative of a breathing process; and an input for receiving a respiratory initiation signal, different from the electroencephalographic signal, capable of indicating a respiratory initiation time. The detection system further includes means for specifying a beta frequency band comprised between 15 and 30 Hz and with a width comprising between 5 and 10 Hz; means for processing the measured electroencephalographic signal, configured for processing the measured electroencephalographic signal as it is being acquired, in the sole specified beta frequency band; and means for identifying, for each breathing cycle, an improper adjustment of the ventilator from the electroencephalographic signals processed in the sole beta frequency band.

Abstract: The present invention relates to an in vitro method for determining that an individual is at risk of developing Alzheimer's disease, which comprises: —determining whether the individual harbours at least one variant allele of a susceptibility gene selected from the apolipoprotein J gene (APOJ) and the complement component receptor 1 gene (CR 1); —deducing that if the individual harbours at least one variant allele of the APOJ and/or CR1 gene, then the individual is at risk of developing Alzheimer's disease.

Abstract: The present invention relates to 1,4-dihydropyridine derivatives of the formula (I) and their uses in the treatment and/or prevention of diseases and disorders directly or indirectly associated with the modification (increase or decrease) of the activity of the cannabinoid receptor 2 (CB2).